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ihe Heart Failure Society of America (HFSA) represents
he first organized effort by heart failure experts from the
mericas to provide a forum for all those interested in heart
ailure research and patient care. The annual scientific
eeting brings together cardiologists, surgeons, nurses, and
llied health care professionals to discuss recent advances in
eart failure, including basic, translational, and clinical
esearch and clinical care. The HFSA also seeks to promote
ollaborative efforts between government, industry, and
cademia on policy development and research. Representa-
ives from all 3 areas participated in the 2006 annual
eeting, which had more than 3,000 attendees.
The HFSA consists of professionals involved in basic
cience, clinical medicine, and patient management focusing
n heart failure. The 10th annual scientific session, co-chaired
y Drs. Stephen Gottlieb and Douglas Mann, included a
ariety of formats: a plenary session, debates, how-to ses-
ions, oral abstract sessions, late breaking clinical trials, as
ell as a number of simultaneous sessions on new research
basic and clinical) and patient care issues. This is a report
f meeting highlights.
pening Session—Accessibility of
uality Health Care: Only If You Can Afford It?
he Opening Plenary Session began with a President’s
ddress by Gary S. Francis (President, HFSA 2004 to
006) that focused on the importance of creativity in
roducing improvements in our understanding and treat-
ent of heart failure. His conclusion that creativity and
ersistence will be required to address the still-unresolved
roblems of heart failure also applies to the problems of
nsurance and health care delivery. The next 3 speakers
ocused on the problem of providing insurance to all
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uced by our present health system, but they differed on the
est solution.
Kevin Grumbach (Professor and Chair, University of
alifornia San Francisco Department of Family and Com-
unity Medicine, University of California, San Francisco,
alifornia) addressed “The Promise of Universal Health
are” from the perspective of a single-payer system. Draw-
ng an analogy to heart failure, Dr. Grumbach characterized
he health care financing system in the U.S. as suffering
rom poor output, swollen costs, and increased afterload.
e cannot “circulate health insurance to cover the entire
opulation,” so we have poor performance with respect to
ealth care access and ultimately outcomes. We have issues
f affordability and waste and “afterload” or resistance
mong many special interests to the changes necessary to
reate a healthier finance system. More than 46 million
dults in the U.S. are without health insurance, resulting in
8,000 unnecessary deaths annually according to the Insti-
utes of Medicine. Despite the fact that we spend twice as
uch on health care as other developed countries, we rank
7th of 191 countries evaluated by the World Health
rganization. Grumbach believes that the only definitive
reatment for treating our diseased health care financing
ystem is to remove it and “transplant” a new healthy
ingle-payer public health insurance system. It would be
Medicare for all.” Patients could choose any provider in
his capitated care system similar to that in use already in
anada and Europe. He concluded that such a system is the
implest and most effective way to ensure comprehensive
are and will not involve additional expenditures.
Robert E. Moffitt (Director, Center for Health Policy
tudies, The Heritage Foundation, Washington, DC)
ook an opposing viewpoint in “The Private Sector is the
nswer.” Dr. Moffitt suggested economic discipline rather
han “surgical interventions.” When attempting any reform,
ne must consider both cost and quality. “You can really
ess things up with the best of intentions.” He emphasized
hat about 84% of Americans have public or private health
nsurance. Most, but not all, of the uninsured are young,
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et insurance through their job. Additionally, most of the
ninsured are in and out of coverage. He believes that the
ocus should be on expanding insurance coverage options for
eople working in small businesses and helping people
etain coverage once they have it. His answer is to tie
nsurance to the person and not the job. Universal coverage
an be attained by changes in the tax code that would give
eople a credit to buy health insurance independently.
eople would be required to buy at least catastrophic
overage to protect themselves and their families. Tax
eform would be tied to reform of the insurance market.
he rules for insurance would be uniform throughout the
ountry. This approach would create a large national insur-
nce pool and a diversity of options.
Len M. Nichols (Director, Health Policy Program, New
merica Foundation, Washington, DC) addressed the “Fu-
ure of Health Care” and was optimistic. He emphasized that
he focus should be on value per dollar rather than on cost
lone. Health insurance is growing increasingly out of reach
or a growing percentage of the workforce. However, there
as been no sense of urgency to make deep changes, because
ey incentives remain unchanged. “You could not design a
ystem with worse incentives.” He believes that we cannot
olve the cost issue without worrying about quality and
ccess. What is required is the “brave new world of shared
esponsibility.” We have to develop information support
ools, solve the malpractice problem, “turbocharge” incen-
ives to pay for services that make and keep people healthy,
nd determine which patients should get which technolo-
ies for which diseases. Optimistically, he sees a growing
onsensus that something must be done, and a convergence
f ideas among Democrats and Republicans. Action may
esult from the predicted importance of health care in the
008 presidential elections.
he Economic Burden of
reating the Sickest of the Sick
n a session that built on the themes of the opening plenary
ession, the cost of health care for heart failure patients was
iscussed. Harlan M. Krumholz (Yale University, New
aven, Connecticut) presented data illustrating the con-
inuing increase in health care spending in the U.S. as a
ercentage of gross domestic product and the various
omponents accounting for the increase. The U.S. stands
ead and shoulders above other countries in health care
pending, with approximately 16% of gross domestic prod-
ct. Heart disease is the number one driver of the increase
n health care spending. Although we have heard for years
hat spending has been going up with little effect on overall
pending patterns, he believes that there will be changes.
ecause resources are finite, physicians face cuts in Medi-
are payments, and out-of-pocket costs for patients will
ncrease. oPaul A. Heidenreich (Stanford
niversity, Stanford, California)
ddressed the specific costs of
eart failure. Close to $35 billion
s spent on heart failure in the
.S. annually, accounting for ap-
roximately 1.5% of health care
pending. Two-thirds of heart
ailure costs are for hospitaliza-
ions, with 10% of all hospital-
zations in the U.S. being for
eart failure; each hospitalization
osts approximately $8,000 to
10,000. Drug costs are substan-
ial as well. Heart failure drug
osts have increased 22% during
ust 2 years. A study of the Medi-
are population in 2000 to 2001
ound that each heart failure pa-
ient took 7.5 medications, ac-
ounting for approximately
4,000 in terms of 2006 whole-
ale prices. Some interventions
ay reduce costs, but others can
e very expensive.
Gillian Sanders (Duke Uni-
ersity, Durham, North Caro-
ina) spoke about the cost-
ffectiveness of ICD and cardiac
esynchronization therapy (CRT)
evices for heart failure. Gener-
lly, interventions that cost less
han $50,000 per life-year are considered a good value; those
etween $50,000 and $100,000 in a gray zone; and more
han $100,000 too expensive. Depending on the study
opulation analyzed and the projected life expectancy, the
ost per life year of ICDs in a primary prevention popula-
ion ranges from $34,000 to $232,000. The cost-
ffectiveness is more favorable the longer the patient lives,
nd most analyses show that the ICD is a good use of our
esources in the primary prevention population. In terms of
RT, the cost per quality life year may be better than ICDs.
he cost in the CARE-HF (Cardiac Resynchronization Heart
ailure Study) has been estimated to be €19,319 per year and,
n the COMPANION (Comparison of Medical Therapy,
esynchronization, and Defibrillation Therapies in Heart
ailure) trial, it was $19,600 per year. Dr. Sanders believes
hat the present challenge is to do a better job of risk
tratification.
In a presentation on the cost-effectiveness of disease
anagement programs, Gregory L. Freeman (University of
exas Health Sciences Center, San Antonio, Texas) stated
hat although early evidence suggests these programs im-
rove health outcomes, they do not save money. However,
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Highlights of 2006 HFSA Scientific Sessions February 6, 2007:608–15isease-management programs more accurately, reducing
xpenses, and improving patient and physician buy-in can
elp improve cost effectiveness. He believes that the results
f early studies of disease management seemed too good to
e true, and they were.
ebates
hould practice guidelines mandate the management of
eart failure patients? The utility of practice guidelines
as debated by Marvin Konstam (Tufts-New England
edical Center, Boston, Massachusetts) and Jay Cohn
University of Minnesota, Minneapolis, Minnesota).
r. Konstam argued the “pro” point of view; practice
uidelines are necessary to manage the increasing number of
eart failure therapies that have demonstrated efficacy in
linical trials and to ensure their proper use. When you have
o much to work with, a guideline is needed to determine
hat constitutes standard therapy. He stated that many
ospitals and physicians are not following simple measures
roven to improve outcomes in heart failure, such as
ssessment of left ventricular function and the use of
ngiotensin-converting enzyme (ACE) inhibitors. The way
o improve compliance and care is to follow guidelines and
andate selected measures. Without guidelines, you will
ot have a process for improving patient care.
Dr. Cohn agreed that guidelines are a valuable source of
nformation, but he argued that they should not mandate
are. They should contribute to individual therapy decisions,
ut patients vary. Guidelines do not address issues such as
herapeutic goals, individual differences, comorbidities, and
ose-response curves. Guidelines also do not address limi-
ations in outcomes research that forms the basis of guide-
ines, such as the mechanism of benefit, the relationship
etween efficacy and safety, and identification of who
enefits from a particular therapy. Furthermore, adverse
vents may counteract efficacy.
hich drug should be added after a beta-blocker and
CE inhibitor? A 3-way debate addressed the issue of
hat drugs should be added to heart failure patients who are
eceiving beta blockers and ACE inhibitors. Anne L. Taylor
University of Minnesota, Minneapolis, Minnesota) pre-
ented the case for the combination of isosorbide dinitrate
nd hydralazine. She argued that the population with heart
ailure differs from the populations in randomized clinical
rials of heart failure drugs. African Americans, the elderly,
nd children are under-represented, and there may be
eterogeneity of responses. Because clinical trials suggest a
ifferent response to drugs among African Americans, she
rgued that the A-HeFT (African American Heart Failure
rial) study shows that African American patients with
eart failure should receive isosorbide dinitrate and hydral-
zine in their treatment regimen.
Bertram Pitt (University of Michigan, Ann Arbor,
ichigan) presented the case for aldosterone antagonists.nimal studies and clinical trials, including the RALES rRandomized Aldactone Evaluation Study), EPHESUS
Eplerenone Post-AMI Heart Failure Efficacy and Survival
tudy), and EMPHASIS-HF (Effect of Eplerenone Versus
lacebo on Cardiovascular Mortality and Heart Failure
ospitalization) trials, suggest an aldosterone antagonist
hould be added to a beta-blocker and ACE inhibitor
herapy before an angiotensin II receptor blocker (ARB).
e did agree that the situation with regard to African-
merican patients is less certain. Thus, he believes that a
arge-scale randomized trial is necessary to determine when
sorbide nitrate and hydralazine, aldosterone antagonists,
nd ARBs should be added as a treatment after beta-
lockers and ACE inhibitors.
Christopher B. Granger (Duke University, Durham,
orth Carolina) argued strongly that ARBs have the most
vidence for their use. There were a small number of events
n the A-HeFT study, the trial was stopped early, and the
urves were converging with short follow-up. The results of
he RALES trial only showed that spironolactone is great
or a small number of patients who are diagnosed with New
ork Heart Association (NYHA) functional class IV heart
ailure, who have normal levels of creatinine, and who
eceive careful monitoring. He stated that physicians in the
eal world cannot follow the potassium monitoring protocol
sed in RALES and, thus, hyperkalemia has been a prob-
em. In contrast, ARBs have the best evidence from the
HARM (Candesartan in Heart Failure) trial, the largest
ontemporary experience across the spectrum of heart fail-
re population with long-term follow-up.
ecent and Late Breaking Trials
ix trials were presented at the late-breaking trial session.
ome of them addressed analyses that showed that sub-
roups of large studies might benefit from the intervention.
he consensus was that, although intriguing, such sub-
roups need to be tested prospectively.
IX-CHF-4 (Non-Excitatory Cardiac Contractility
odulation Device for Advanced Heart Failure). Martin
orggrefe (University Hospital Mannheim, Mannheim,
ermany) presented FIX-CHF-4, a pilot study addressing
hether an implantable device providing electrical stimula-
ion during the absolute refractory period and intended to
trengthen cardiac contractility can increase exercise toler-
nce and improve quality of life. Cardiac contractility
odulation therapy is delivered via a system consisting of an
mplantable pulse generator and 3 transvenous pacing leads.
ecause of high energy requirements, the device battery
ust be recharged with an external unit. The multicenter,
rospective, double-blind, crossover study enrolled 126
atients in NYHA functional classes II and III with an
jection fraction 35% who had medically refractory heart
ailure and were not eligible for CRT. All devices were
witched off at implant and subsequent visits to ensure
linding. After a 2-week run-in period, patients were
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February 6, 2007:608–15 Highlights of 2006 HFSA Scientific Sessionshe patients in group 1 had the device turned on, whereas
he patients in group 2 had devices that were deactivated.
n the second 12-week phase, patients were crossed over.
he results showed that in the first 12-week phase exercise
olerance measured by peak VO2 increased steeply in both
roups of patients, suggesting a strong placebo effect. In the
econd 12-week crossover phase, there was further improve-
ent in the patients whose device was switched on and a
eturn to baseline in those with devices that were switched
ff (p  0.02). A similar pattern was seen in Minnesota
iving with Heart Failure scores, with both groups showing
mprovement during the first phase, and a divergence
avoring patients with devices switched on during the
econd phase (p  0.03). No significant differences in time
o death or first hospitalization were seen between the 2
roups during the first phase, but there was a trend toward
ewer deaths and hospitalizations in the group with the
evices switched on during the second 12-week phase.
here were three deaths in the study, all during the
ff-phase. The most common procedure-related adverse
vents were bleeding (4%), infection (2%), and lead dis-
odgement (2%), with fewer events occurring during the
n-phase than during the off-phase.
CTIVE-W (Atrial Fibrillation Clopidogrel Trial with
rbesartan for Prevention of Vascular Events-W).
kshay S. Desai (Brigham and Women’s Hospital, Boston,
assachusetts) presented this analysis of the ACTIVE-W
tudy. The previously reported ACTIVE-W study, which
as stopped early, found an overwhelming benefit for oral
nticoagulation compared with a combination of clopi-
ogrel and aspirin. Because heart failure outcomes were
djudicated in the ACTIVE-W study, there was an oppor-
unity to look closely at the effect of aspirin on composite
eart failure outcomes in a large prospective randomized
rial. The question is of interest because prior randomized
rials of ACE inhibitors have suggested that aspirin may
ttenuate the benefits of ACE inhibitors in patients with
eart failure. This post-hoc analysis of the ACTIVE-W
tudy included 2,031 patients with a previous history of
eart failure. The analysis found that these patients were
uch more likely to reach the composite end point of death
r heart failure-related hospitalization than the general
CTIVE-W study population. However, there was no
ignificant difference between the oral anticoagulant and the
spirin/clopidogrel groups on the primary end point, com-
onents of the primary end point, and another composite
nd point of heart failure-related hospitalization, stroke,
yocardial infarction, or vascular death. This was true
egardless of the use of ACE inhibitors. This retrospective
nalysis suggested that there is no important interaction
etween ACE inhibitors and aspirin in the study popula-
ion. Dr. Desai noted many limitations. The ACE inhibi-
or/aspirin analysis was not prespecified, patients were not
andomized to ACE inhibitors, low doses of aspirin were
iven, and the study population included a broad spectrum
f left ventricular ejection fractions. cffects of the adenosine A1 receptor antagonist KW-
902, alone or in combination with furosemide.
rs. Barry M. Massie (University of California, San Fran-
isco, California) and Michael M. Givertz (Brigham and
omen’s Hospital, Boston, Massachusetts) updated the
udience on 2 studies that evaluated the dose-dependent
ffects of the adenosine A1 receptor antagonist KW-3902
n diuresis and renal function in patients hospitalized with
cute decompensated heart failure. The CKI-201 study
nvolved patients hospitalized with acute decompensated
eart failure with renal impairment, whereas the CKI-202
tudy involved patients refractory to high doses of conven-
ional diuretics.
The 146 patients participating in the CKI-201 study
eceived 1 of 4 doses of KW-3902 in a 2-h intravenous
nfusion for up to 3 days. KW-3902 or the placebo was
iven as monotherapy for the first 6 h on the first day.
hereafter, intravenous loop diuretics could be given as
ndicated. The primary end point of the study was 6-h urine
utput on the day of discharge or day 4, whichever came
rst. Results presented by Dr. Massie showed that patients
eceiving KW-3902 had increased urine volume and re-
uired less furosemide than the placebo group.
The CKI-202 study was a small dose-escalation study
xploratory study with 36 patients. Of the patients, 24 were
ivided into 3 escalating-dose groups and 12 received
lacebo. After a 3- to 5-h baseline period during which
iuretics were withheld, a 2- to 3-h infusion of KW-3902
as given. Rescue furosemide was allowed. The primary end
oint was change in hourly urine volume, and the secondary
nd point was change in creatinine clearance. Results
resented by Dr. Givertz showed a progressive reduction in
rine output in the placebo group during the 9-h period.
atients receiving KW-3902 had a trend toward increased
rine output. In regard to creatinine clearance, the placebo
roup had a trend toward worsening renal function. The
atients receiving 30 mg of KW-3902 had improved creat-
nine clearance, achieving statistical significance.
Combined analysis of both studies showed that approx-
mately one-third of the patients experienced a serious
dverse event. One patient receiving a 60-mg dose experi-
nced a seizure. Dr. Givertz noted that there is a large body
f evidence confirming that adenosine modulates the seizure
hreshold and that adenosine A1 receptor antagonists may
recipitate seizure in those at risk, but probably not in those
ho are risk-free. Results of both studies suggest that
W-3902 has diuretic properties and that the drug may
ave a renal protective effect in patients receiving loop
iuretics, allowing lower diuretic doses and facilitating
arlier discharge. An ongoing study with a target enrollment
f 1,200 patients hospitalized with acute heart failure and
olume overload will further assess efficacy.
esults of a first human study of a novel calcium-
ndependent inotrope. John R. Teerlink (University of
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Highlights of 2006 HFSA Scientific Sessions February 6, 2007:608–15he drug is a small molecule activator of cardiac myosin,
hich has a novel mechanism of action, and was found to
ncrease cardiac output and contractility in dog studies
hrough an increase in left ventricular systolic ejection time.
t is hoped that CK-1827452 can increase cardiac efficiency
n humans without the disadvantages of current inotropes,
hich increase intracellular calcium, heart rate, and oxygen
emand. The primary objective of the Phase 1 study was to
etermine the maximum tolerated dose. The study enrolled
4 healthy male volunteers who received 6-h continuous
nfusions of the drug or a placebo. There were 4 study days
t least 1 week apart. Ascending doses of CK-1827452
anging from 0.005 mg/kg/h to 1.0 mg/kg/h and a random-
zed placebo were administered. The maximum tolerated
ose was 0.5 mg/kg/h. Higher doses resulted in excessive
rolongation of ejection time, which decreased diastolic
lling. There were 3 premature terminations at the higher
oses. There was a strong dose-dependent increase in
ystolic ejection time. Similarly, there was a statistically
ignificant dose-dependent increase in fractional shortening
nd ejection fraction. There was no evidence of QT pro-
ongation. There were adverse events, including postural
izziness, headache, and dizziness, but there was no increase
n the frequency of adverse events up to the maximum
olerated dose. The results of this study have provided the
asis for initiating additional studies in patients with heart
ailure.
CCLAIM (Advanced Chronic Heart Failure Clinical
ssessment of Immune Modulation Therapy). Guill-
rmo Torre-Amione (Methodist Hospital, Houston, Texas)
pdated the audience on the ACCLAIM study, a trial
esting whether a novel immune modulation therapy (IMT)
ill reduce mortality or cardiovascular hospitalization in
atients with advanced systolic heart failure. The therapy
nvolves collecting a blood sample from the patient, deliv-
ring oxidative stress to the sample with a special system,
nd then injecting the autologous sample intramuscularly.
he trial randomized 2,426 patients with NYHA functional
lass II to IV heart failure and a left ventricular ejection
raction30% to receive IMT or placebo. Three treatments
ere administered in an induction treatment phase on days
, 2, and 14 and then followed with maintenance treatments
t 4-week intervals for a minimum of 8 treatments. There
as no difference between the 2 groups regarding the
rimary end point of all-cause mortality or cardiovascular
ospitalization or in key secondary end points. There was a
ignificant improvement in measurements of quality of life
n the IMT group. IMT was safe and well-tolerated, and
he number of adverse events was balanced between the 2
roups. The results of prespecified subgroup analysis found
hat IMT therapy was better than placebo in patients
ithout a previous myocardial infarction and in those with
previous myocardial infarction whose symptoms had not
rogressed beyond NYHA functional class II. Dr. Torre-
mione concluded that the findings provide a basis for onother trial to study the patient population that seemed to
enefit from IMT.
PT-CHF (Oxypurinol Therapy for Congestive Heart
ailure). Joshua M. Hare (Johns Hopkins University
chool of Medicine, Baltimore, Maryland) presented the
PT-CHF study, in which the safety and efficacy of
xypurinol, a xanthine oxidase inhibitor, was studied. An
bundance of preclinical studies in animal models of heart
ailure demonstrate that xanthine oxidase inhibition reverses
emodeling and improves mechanoenergetics, endothelial
unction, and survival. The OPT-CHF study randomized
05 patients with NYHA functional class III or IV heart
ailure with a left ventricular ejection fraction 40% who
ere receiving stable and optimal therapy for heart failure.
atients received either 100 mg/day of oxypurinol for 1
eek followed by 600 mg/day or placebo. Patients were
ollowed for 24 weeks. A composite clinical end point was
sed in which patients were classified as improved if NYHA
unctional class or global assessment improved; worsened if
he patient died or was hospitalized for worsening heart
ailure, required a new heart failure medication, or if NYHA
unctional class or global clinical status worsened; or un-
hanged. Results showed no effect of oxypurinol on the
rimary composite end point. However, upon analysis of
econdary end points, researchers found a significant de-
rease in serum uric acid levels starting at approximately 4
eeks into the trial and persisting throughout the follow-up
eriod in the oxypurinol group. A subgroup analysis found
hat patients with high baseline levels of serum uric acid
9.5 mg/dl) appeared responsive to oxypurinol whereas
hose with lower levels did not. The findings suggest that
erum uric acid levels may be a biomarker in heart failure
llowing targeted therapy.
are of Heart Failure Patients
here were numerous sessions on various aspects of caring
or heart failure patients. Some of these included discussions
f sleep apnea, brain natriuretic peptides (BNPs), and
mplantable defibrillators.
leep-disordered breathing and heart failure. The session
n sleep apnea was very well attended, attesting to the
nterest in the subject. Steven M. Scharf (University of
aryland, Baltimore) discussed who should be evaluated for
leep-disordered breathing. He asked the question whether
leep apnea should be considered in every patient with heart
ailure. Because sleep-disordered breathing is common and
ay contribute to heart failure, physicians should be con-
erned about the possibility of sleep abnormalities. How-
ver, studying every patient with polysomnography is ex-
ensive, and there is no conclusive evidence that treatment
mproves mortality and quality of life. He thus recom-
ended that all patients have clinical screening, and those
ith a high risk of sleep-disordered breathing be studied
sing polysomnography. These would include patients with
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ximetry for other patients and full evaluation if frequent
esaturation episodes.
David White (Harvard University, Boston, Massachusetts)
nd Barbara Phillips (Lexington, Kentucky) talked about the
reatment of sleep apnea. They acknowledged that the effects
f treatment are still unclear. They showed the minimal data
n oxygen and theophylline, and more extensively discussed
ontinuous positive airway pressure (CPAP). Although
here are no firm data demonstrating the long-term efficacy
n heart failure of CPAP, this is the standard treatment.
he risks and side effects of CPAP were discussed, includ-
ng rhinorrhea, nasal congestion or dryness, epistaxis, skin
brasions and rashes, chest discomfort, claustrophobia,
erophagy, and sinus discomfort. Compliance is certainly a
ajor problem with CPAP. Other treatments, such as oral
ppliances and surgery, also were discussed. Uvulopalato-
haryngoplasty has not been well studied and has approxi-
ately a 50% response rate, although there is also the
ossibility of relapse. A review from the Cochrane Database
oncluded that there is insufficient evidence to recommend
he use of drug therapy in the treatment of obstructive sleep
pnea. However, behavioral treatment, including weight
oss, lateral decubitus sleeping position, smoking cessation,
voidance of muscle relaxants, and avoidance of sleep
eprivation, should be performed.
Virend K. Somers (Rochester, Minnesota) talked about
ossible mechanisms linking sleep apnea to heart failure.
here are reasons to suspect inflammatory effects from
ltered oxygen tension resulting from apenic episodes,
ympathetic activation, hypertension, arrhythmias, and im-
aired endothelium mediated vasodilation.
he utility of BNP measurements. One session addressed
he latest information about natriuretic peptides. John
urnett and Margaret Redfield (Mayo Clinic, Rochester,
innesota) addressed the different forms of BNP and
-terminal prohormone brain natriuretic peptide (NT-
roBNP). Because proBNP is cleaved into NT-proBNP
nd BNP, different assays may not be detecting the same
olecule. Thus, determining the activity of various forms
nd the extent to which they circulate in the blood is
mportant. Dr. Burnett focused on the physiology of the
ifferent natriuretic peptides. He provided evidence that,
lthough traditional assays report high measured levels of
NP-32 in advanced heart failure, a highly specific assay
hows low concentrations of the usual active form. The
ssay may be detecting an inactive form; the studies suggest
n absence of circulating BNP-32 in patients with
dvanced-stage heart failure and argue for the existence of
ltered forms of BNP that are contributing to the usual
easured values. In addition, interactions among various
irculating BNP forms could affect activity. He concluded
hat immunoreactive BNP is markedly elevated in plasma in
uman congestive heart failure, but this immunoreactive
NP may have reduced amounts of BNP 1-32. Other
irculating forms may include pro-BNP 1-108, NT- croBNP 1-76, and BNP 3-32. These additional forms have
ifferent levels of cyclic guanosine monophosphate activity.
r. Redfield presented additional data showing that there
ight be alternate BNP forms in patients with heart failure.
bnormal proBNP processing, alternate gene splicing, pro-
essing, digestion, and formation of dimers or trimers all
ight affect both measurement and activity of these forms.
he biological activity of altered forms remains unclear. She
osed the questions whether proBNP circulates in signifi-
ant amounts, whether “BNP” or “NT-proBNP” assays
ross react with proBNP and whether proBNP is biologi-
ally active.
he problems of measuring. Milton Packer (University of
exas Southwestern, Dallas, Texas) and Stephen Gottlieb
University of Maryland, Baltimore, Maryland) addressed
he limitations of the use of BNP and NT-proBNP assays.
oth emphasized that the concentrations of natriuretic
eptides are affected by many factors. Although studies
how that BNP and NT-proBNP concentrations can pre-
ict the presence of heart failure, its clinical utility in
ifficult patients not in studies is controversial. Patients in
ntensive care units have elevated concentrations, unrelated
o volume status. Obesity lowers concentrations of BNP and
T-proBNP, whereas renal dysfunction, pulmonary disease
nd age elevate the concentrations. Even the chronicity or
everity of disease might impact upon the concentration.
hus, it is not surprising that the relationship between left
entricular filling pressures and natriuretic peptide concen-
rations is poor. Both Dr. Packer and Dr. Gottlieb empha-
ized that these other factors must be considered when
valuating a clinically obtained value.
imitations of ICDs. A joint session with the Heart
hythm Society addressed a theme that has received much
ublic scrutiny during the past year. William G. Stevenson
Brigham and Women’s Hospital, Boston, Massachusetts)
pened the session with a presentation on “Who Should
et an ICD: 2006.” This presentation focused on the use of
CDs for the primary prevention of sudden cardiac death.
he use of ICDs reduces mortality across the spectrum of
eart failure. However, application of the American College
f Cardiology/American Heart Association/European So-
iety of Cardiology 2006 and Centers for Medicare and
edicaid Services guidelines on ICDs in primary preven-
ion will yield an absolute annual survival benefit between
.5% and 7%. With this potential benefit, there are concerns
bout cost/benefit. This has led to efforts to develop risk
tratification criteria (such as the absence of T-wave alter-
ans) to exclude patients at low-risk of sudden cardiac
eath. He stated that the cost/benefit case for CRT is
etter. We can expect to see efforts to improve the cost/
enefit ratio in the coming years through reduced cost,
etter patient selection, and consideration of improvements
n quality of life and reduced hospitalizations.
Lynne Warner Stevenson (Brigham and Women’s Hos-
ital, Boston, Massachusetts) then addressed patient con-
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o provide patients with better information about expected
utcomes with heart failure therapies. The use of ICDs for
rimary prevention may reduce mortality by 22%, but 78%
f deaths still occur. We should let patients know approx-
mately how many patients with their condition will be
aved by an ICD during the next 5 years, how many will die
nyway, and how many will not need them at all. We should
lso present information on inappropriate shocks and other
omplications and listen to patients who request that their
evice be turned off to allow a natural death. It is difficult to
alk about death and modes of death, but critical to do so.
Mark D. Carlson (Case Western Reserve University,
leveland, Ohio) discussed a topic much in the news—ICD
eliability. We experienced a “perfect storm” in 2005, as
ach of the 3 major ICD manufacturers issued product
dvisories. There were some patient deaths, thousands of
evices were explanted, and patient and physician confi-
ence in the therapy was shaken. Explanting and replacing
he devices is not trivial and the risks involved may be
reater than the risk of device failure. These problems
esulted in many patients who could benefit from the
herapy not receiving it, a problem that continues. Cur-
ently, there are guidelines being developed regarding pace-
akers and ICDs. There is no such thing as a perfect
uideline, but with enhanced transparency we should have
etter knowledge that will enable wise decisions and restore
onfidence and trust in this therapy.
Bruce Wilkoff (Cleveland Clinic, Cleveland, Ohio) con-
luded with a talk on managing the morbidity of ICD
herapy. Devices are less than the perfect. When consider-
ng their use, we need to weigh the risks and benefits of
CD therapy. Risks include infections, device problems,
ocietal restrictions, and shocks. On the other hand, ICDs
re dramatically effective in reducing the mortality of ven-
ricular arrhythmias. All of the talks emphasized that we
eed to help patients make informed decisions.
he Challenges and Relevance of Global Studies
ne session at the annual scientific meeting provides an
pportunity for industry and academia to come together to
iscuss issues of concern to both groups in a balanced
on-threatening forum. This year’s topic focused on the
dvantages and disadvantages of global clinical trials.
articipants included Cesare Orlandi (Otsuka Maryland
esearch Institute, Rockville, Maryland), Beat Knusel
Amgen, Inc., Thousand Oaks, California), Marc Pfeffer
Brigham and Women’s Hospital, Boston, Massachu-
etts), Robert M. Califf (Duke University, Durham, North
arolina), and John G. F. Cleland (University of Hull,
ingston upon Hull, United Kingdom). Dr. Knusel ex-
lained that global studies were needed because the phar-
aceutical industry operates in a global market and global
tudies facilitate product registration and adoption of the
rug. There is also a need to find participants amid pompetition from many studies in the U.S. Global studies
an demonstrate robustness of the treatment effect or
dentify differences in treatment effect across regions and
thnic groups. Dr. Pfeffer emphasized that global trials
resent the opportunity to reduce morbidity and mortality
s well as reduce the economic burden and enhance inter-
ational collaboration. However, global studies pose limi-
ations in terms of logistics and trial implementation,
ncluding differing treatment standards, the infrastructure to
upport clinical trials, translation, regulatory timelines, and
atient protection.
In addressing the question of how to design a perfect
lobal study in heart failure, Dr. Califf said that trials should
e better at answering questions of importance to patients,
ractitioners, and the healthcare system. Trials should
dvance knowledge and raise new questions, and must be
esigned to ensure the independence of data monitoring.
r. Cleland pointed out the need for study populations to
e representative of the target populations. If a heart failure
tudy is conducted in Russia, the patients will be 10 years
ounger than patients in United Kingdom or North America,
nd they will have fewer comorbidities. He believes we
hould do trials that more closely resemble clinical practice
nd be wary of excessively large studies; large trials that are
topped early because of statistically robust effects may
onetheless be clinically irrelevant. Dr. Cesare Orlandi
oncluded by stressing the need for simplicity, given the
omplexities involved in global clinical trials.
asic Science Session
special session before the meeting addressed recent
dvances in basic science related to heart failure. These
resentations generally showed how evidence of abnormal
oncentrations or activity of a substance could lead to
nvestigation in vitro or in animals and demonstrate the
mpact of the involved pathway on cardiac function.
Jeffery D. Molkentin (Cincinnati Children’s Hospital
edical Center, Cincinnati, Ohio) discussed growth-
ifferentiation factor (GDF)-15, which is up-regulated in
ardiomyopathic transgenic mice. The subsequent work
howed that the loss of GDF-15 severely compromises the
bility of the heart to adapt to stress stimulation and that the
verexpression of GDF-15 in the heart protects it from
timuli that would otherwise induce hypertrophy or failure;
verexpression in cardiomyocytes reduces agonist-induced
ypertrophy. Systemic delivery of GDF-15 protects the
eart and attenuates failure in MLP/ mice. He further
uggested that GDF-15 may exert its protective and anti-
ypertrophic effect through the SMAD2/3 pathway.
Helmut Drexler (Medizinische Hochschule, Hannover,
ermany) discussed CCN1. CCN1-deficient mice are em-
ryonic lethal as the result of severe vascular defects,
ncluding disruption of vessel integrity, reduced bifurca-
ions, and reduced vascular endothelial growth factor ex-
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hat pressure overload, stretch, ischemia, and neurohor-
onal factors, such as Ang II or alpha1-adrenergic stimuli,
nduce myocardial expression of CCN1, a potent proangio-
enic factor. In turn, CCN1 promotes proliferation of
ndothelial cells. Furthermore, CCN1 induces release of
rowth factors, chemokines and cytokines from CD34
ells.
Victor J. Dzau (Duke University, Durham, North Carolina)
alked about Akt-regulated stem cell paracrine factors. After
howing that mesenchynmal stem cells (MSC) modified
ith Akt prevented remodeling in infracted hearts, his
aboratory tried to determine why. They hypothesized that
kt-MSC mediates myocardial survival and repair by se-
retion of factors. They showed that Akt-conditioned media
nduced cardiomyocyte apoptosis. To find the possible
ediators, they used microarray profiling of mesenchymal
tem cells with and without Akt to identify likely candi-
ates. They then performed in vitro and in vivo functional
esting of candidate genes. Dzau and colleagues showed
ow they have identified Sfrp2 as a candidate prosurvival
actor; prosurvival effects on cardiomyocytes of Akt-MSC
onditioned medium are lost upon Sfrp2 knockdown.
John M. Kyriakis, (Tufts-New England Medical Center,
oston, Massachusetts), discussed the p8 protein. He
howed that there is induction of p8 protein in the failing
uman heart, which is reduced with mechanical unloading.
e then showed that cardiomyocyte p8 is induced by
ndothelin-1 and p8 is required for ET-1–stimulated car-
iomyocyte hypertrophy. Subsequent work showed that
umor necrosis factor (TNF) induces primary cardiac fibro-
last p8 through both transcriptional and post-translational
echanisms. p8 is up-regulated and stabilized by TNF- in
ardiac fibroblasts, and p8 is required for TNF-stimulated
p-regulation of MMP-13 and -9. Furthermore, p8 is
equired for the induction, in primary cardiac fibroblasts, of
MP-9 and -13, and p8 binds to chromatin containing the
MP-9 and -13 promoters. As with the other work
resented in this session, Dr. Kyriakis showed how identi-
cation of changes of a molecule (in this case p8) can be
ollowed by the determination of its function by careful in
itro and in vivo work.
Michael Schneider (Baylor College of Medicine, Houston,
exas) focused on the Cdk9/PGC-1 axis as a therapeutic
arget. Cyclin-dependent kinase-9 (Cdk9) is related to cell
ycle proteins that control proliferative growth, but its chief
uole, instead, is in gene expression, where it acts as one of
everal Cdks that phosphorylate the RNA polymerase
esponsible for most mRNA transcription. Cdk9 activity is
levated by multiple cardiac stress signals (workload,
gonist-dependent signals via the guanosine triphosphate-
inding protein Gq, and calcium-dependent signals via
alcineurin) and is increased in human heart failure as well.
hese chronic pathobiological levels of Cdk9 activity were
imicked in transgenic mice, with the result being concen-
ric hypertrophy, plus a marked predisposition to rapidly
ecompensated heart failure if stressed. The mechanism for
he heart becoming sensitized was shown to be the suppres-
ion of a specific transcription factor, PGC-1, that is
ssential for the expression of proteins involved in mito-
hondrial energy production. Thus, stress-induced Cdk9
ctivation is coupled to a master regulator of mitochondrial
etabolism in heart failure. This work supports the logic of
eveloping Cdk9 inhibitors as potential therapy. Interest-
ngly, recent work from Dr. Schneider’s laboratory has
dentified the scaffold protein menage-a-trois-1 (a partner
f the functionally related kinase, Cdk7) as being associated
n a physical complex with PGC-1 and being essential for
GC-1 function and metabolic gene expression in cultured
ells and mouse myocardium.
From basic science to clinical care, the 10th annual
eeting of the Heart Failure Society provided opportunities
or people from various disciplines to look at one problem
heart failure). Ideally, bringing physicians, nurses, pharma-
ists, basic scientists, coordinators, and industry together
an lead to better understanding of the knowledge of other
isciplines. The interaction should lead to improved clinical
are and enhanced research.
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